[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hypothalamic-obesity":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":44,"states":45},"Hypothalamic Obesity",5,4,[8,16,23,30,37],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06299891","Efficacy and Safety of Phentermine\u002FTopiramate in Youth With Hypothalamic Obesity",[12],"Phase 2","RECRUITING","2026-08-26T02:17:16.126291Z","2026-05-05T02:35:31.864813Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06901245","Tirzepatide in PWS, HO and GNSO",[20],"Phase 4","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:27.435945Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06239116","A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment",[27],"Phase 1\u002FPhase 2","2026-08-26T02:15:27.567165Z","2026-05-05T02:43:27.293698Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06760546","A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)",[34],"Phase 3","2026-08-26T02:19:02.550788Z","2026-05-05T02:35:31.931167Z",{"nct_id":38,"title":39,"phases":40,"status":41,"updated_at":42,"content_modified":43},"NCT07156578","A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:16:05.813655Z","2026-06-16T05:54:07.866565Z",[],[46,50,53],{"state":47,"count":48,"slug":49},"Massachusetts",3,"massachusetts",{"state":51,"count":48,"slug":52},"Tennessee","tennessee",{"state":54,"count":48,"slug":55},"Washington","washington"]